Low global SARS-CoV-2 circulation, with WHO reporting roughly 22,000–35,000 cases over recent 28-day periods and CDC data showing COVID-19 emergency department visits at just 0.3 percent, underpins the 96 percent market-implied probability against a new coronavirus pandemic in 2026. No variants currently meet WHO or ECDC criteria as variants of concern, despite monitoring of lineages such as NB.1.8.1 and BA.3.2, while population-level immunity from prior exposure and vaccination limits severe outcomes and exponential spread. Surveillance networks continue to track transmission dynamics and genomic changes, with any shift toward a highly transmissible, virulent novel strain capable of overwhelming existing immunity remaining the primary realistic scenario that could alter the outcome before year-end.